CStone Pharmaceuticals
CSPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $5 | $2 | $1 | $3 |
| - Cash | $0 | $0 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $2 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -83.8% | -39.8% | 25.6% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -187.6% | 44.5% | 67.7% | 74.5% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -538.3% | -55.7% | 1.3% | -169.2% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -546.4% | -69.9% | 6.2% | -78.1% |
| EPS Diluted | -0.1 | -0.084 | 0.012 | -0.124 |
| % Growth | -19.3% | -775.8% | 110% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |